Resultado da Busca
Há 16 horas · Travere pumps brakes on late-stage enzyme replacement ... Filspari won its initial accelerated nod in early 2023 on phase 3 data showing it could significantly cut protein in the urine compared to ...
Há 16 horas · UCB, a global biopharmaceutical company, today announced the first presentation of two-year data from the Phase 3 studies, BE HEARD I and BE HEARD II, and their open-label extension, evaluating ...
Há 3 horas · The Phase 3 clinical program is supported by positive data from the Phase 2 STRIDE clinical trial in which 228 patients were randomized to one of five ESK-001 dose cohorts or placebo. The trial met its primary endpoint, the proportion of patients achieving a PASI 75 at week 12 compared to placebo, and key secondary efficacy endpoints at all clinically relevant doses tested.
Há 3 horas · Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
Há 16 horas · Roche subsidiary Genentech announced on Thursday that Gazyva (obinutuzumab) met its primary efficacy endpoint in the Phase III REGENCY study of lupus nephritis. The pharma will present these data to the FDA and other global health authorities with the goal of securing approvals in this indication. Without revealing specific data, Roche in its ...
Há 2 horas · Alumis Inc. announced positive 28-week data from the open-label extension period of its Phase 2 STRIDE clinical trial of ESK-001. These data were presented during a late-breaking oral session at the...
Há 5 horas · Travere slips after pausing late-stage trial’s enrollments. Travere Therapeutics (NASDAQ: TVTX) lost ~5% premarket Friday after announcing a pause in enrollments in its Phase 3 HARMONY Study for ...
